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Abstract
Objective: The objective of this selective EBM review is to determine whether or not
onabotulinumtoxin-A decreases the frequency of headaches in adults with chronic migraines.
Study design: A review of two randomized controlled trials and one observational cohort that
were published in peer-reviewed journals between 2010-2016.
Data sources: The study reviews were searched through PubMed and were selected based on
types of studies, years they were published, relevance to the clinical question, and outcomes that
were patient oriented.
Outcomes measured: Patient recorded headache diaries and telephone diaries were used to
record the frequency of headaches. Any headache lasting >4 hours were recorded as headache
days in the Diener et al study, while no headache at all was recorded as headache free-day in the
Mathew et al. study.6,7
Results: In the study conducted by Vikelis et al., results showed a decrease in the frequency of
headaches with a p-value <.001.8 In the Mathew et al. study, the results show that decrease of
50% or more was greater in the onabotulinumtoxin-A group compared to placebo; p-value
<.027.6 The second study, conducted by Diener et al., showed that patients treated with
onabotulinumtoxin-A had a significant change from headache day baseline compared to placebo
(p<.001)7
Conclusion: Based off of the results from the studies, it is clear that onabotulinumtoxin-A
decreases the frequency of headaches. All three studies show significant data that support the use
of onabotulinumtoxin-A in decreasing frequency of chronic migraines. Studies used mean
change from baseline and decrease of headache free days out of the month to measure their
outcome.
Key words: Botulinum toxin A, chronic migraine, prophylaxis, chronic daily headache
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Introduction
Migraines are the leading cause of neurologic disability and affect 10% of people
worldwide and about 4 million people in the US.1 A migraine is a benign and recurring type of
headache associated with neurologic dysfunction. They can be accompanied with or without an
aura, although without aura is more common. 2 Migraines are three times more common in
women, and are the second most common cause of a headache. 2,3 Chronic migraine is defined as
experiencing migraines more than 15 days out of the month.
Headaches are a very common complaint in the emergency department and account for
about 1.2 million visits each year.4 It is estimated that $78 billion is spent on migraines in the
United States each year. This number includes all different types of headaches, acute and
chronic. Specifically, $9,364 is spent annually on those dealing with chronic migraines. 5
The specific mechanism of action of migraines is not proven, but it is based on the
hypothesis and knowledge of what is known about the brainstem pathways. It is believed that
serotonin and dopamine play a role in the pathophysiology of migraines, but their exact
mechanism is unclear.1 It is known that migraine attacks have a familial component. Mutations
involving CACNA1A gene are known to cause familial hemiplegic migraines (FHM). 1
Key components of migraine include throbbing or pulsatile pain, nausea, vomiting,
photosensitivity, and pain that is made worse with movement. 1 The usual methods of treatment
for migraines include: avoidance of triggering factors, acetaminophen, ibuprofen, naproxen,
triptans, ergotamines, prochlorperazine, metoclopramide, transcranial magnetic stimulation, and
narcotics.1 Propranolol, amitriptyline, and topiramate can all be used as preventative treatment in
patients with chronic migraines.2. Botox injections can be used as an alternative treatment to
decrease the severity and frequency of migraines in treatment resistant patients.
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Botulinum toxin type A inhibits the release of acetylcholine at the neuromuscular
junction. It is focally administered and is used therapeutically in disorders characterized by
muscle hyperactivity. Onabotulinumtoxin-A can help to treat chronic migraines since it also
inhibits the release of nociceptive mediators such as glutamate substance P, and calcitonin generelated peptide.6
Objective
The objective of this selective EBM review is to determine whether or not “Does
onabotulinumtoxin-A decrease the frequency of headaches in adults with chronic migraines?”
Methods
Two randomized controlled trials and one observational cohort were used in order to help
answer our clinical question. All three articles were found through the database PubMed. Key
words such as botulinum toxin A, chronic migraine, prophylaxis, and chronic daily headache
were all used to help find the appropriate articles. Since the clinical question focused on adults,
articles were selected based on participants that were between the ages of 18-65.
Articles were selected based on types of studies, years they were published, relevance to
the clinical question, and outcomes that were patient oriented. All articles were published in
English in peer-reviewed journals. Inclusion criteria included studies that were RCT and
published after 2009. Exclusion criteria were any studies that included patients less than 18 years
old. A summary of statistics reported were change from baseline, NNT, EER, CER, and p-value,
and a decrease of 50% or more from baseline.
Patients greater than 18 years old who experienced headaches more than 15 days of the
month were used as the population studied in all three studies. The intervention in all three
studies was onabotulinumtoxin-A 100 IU, and 155 IU. The two randomized controlled trials had
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placebo groups which used sodium chloride for comparison. The observational cohort used
patient’s pre-treatment status for comparison.
Table 1- Demographics & characteristics of included studies
Study
Mathew6 Double blind
(2010)
RCT

#
Age
pts (yrs)
355 1865

Inclusion
criteria
Men and
women aged
18-65 who
experiences
headaches more
than 15 days of
the month.
Migraines
included with or
without aura,
episodic/chronic
tension-type

Diener7
(2010)

705 1865

Men/women
aged 18-65 with
hx of migraine
meeting
diagnostic
criteria ICHD-II

Double blind
RCT

Exclusion
criteria
Any medical
condition
putting them at
high risk if
exposed to
botox. Infection
or skin
disorders.
Allergies to
botox. Hx of
“complicated
migraine”,
Previous
therapy with
botox.
Depression
score > 24
(beck),
Pregnant,
nursing, or
planning
pregnancy
“complicated”
migraine.
Conditions that
puts them at
increased risk if
exposed to
botox. Use of
prophylaxis
within 28 days.
Depression
scale >24.
Psychiatric
disorders. Any
childbearing
potential

W/D Interventions
81

100 U clostridium
botulinum toxin
type A VS. placebo
.9 mg sodium
chloride

36

Botox-A 155 U
VS. placebosodium chloride
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Vikelis8
(2016)

Double blind 81
Observational
cohort

>18

Adults with hx
of chronic
headaches

Any
0
contraindication
to botox-A

4

155 UI
onabotulinumtoxinA VS. patient’s
baseline

Outcomes
Patient recorded headache diaries, telephone diaries, and severity by numerical scale
were all used to measure the frequency of headaches. A headache impact test score and
migraine-specific quality of life questionnaire were also used to measure change from patient’s
baseline. A decrease from baseline of 50% or more was considered a significant change when
measuring frequency of headaches. Researchers in the Diener et al. study counted a headachefree day if the patient reported a headache that lasted <4 hours in a 24-hour day. 7 In the Mathew
et al. study, a headache-free day was recorded as no headache at all during a 24-hour period. 6

Results
All studies included adults aged 18 to 65 years old with chronic migraines 15 days or
more out of a 30-day period. Two randomized controlled trials and one observational cohort
compared onabotulinumtoxin-A against either placebo or patient’s baseline to determine if
onabotulinumtoxin-A was able to decrease the frequency of migraines. All inclusion and
exclusion criteria for each study can be found in table 1.
The study conducted by Mathew et al. used mean change from baseline to measure
frequency of headaches. This was determined using patient recorded telephone diaries. Patients
in the study were also asked to record the use of other acute pain medications using electronic
data system. This gave researchers the ability to compare the use of onabotulinumtoxin-A against
the use of other medications.
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Patients were screened during a 30-day baseline period using electronic telephone diaries,
which captured specific characteristics of their headaches as well as use of medication. 6 Of the
571 patients assessed over the baseline period, 355 were enrolled and randomized. 279 patients
were classified as placebo nonresponders and 76 patients are placebo responders. Patients were
randomized within each group to receive either onabotulinumtoxin-A or placebo. 6
A difference of three headache-free days between the onabotulinumtoxin-A and placebo
group, per 30-day period, was considered to be statistically significant. A headache free day was
defined as no headache after a complete day (00.00-23.59). 6 A significantly higher percentage of
participants in the placebo nonresponder group was noted on day 180 to have a decrease of 50%
or more in the frequency of headaches per 30-day period (32.7% vs 15%, p=.027). 6 This means
that 32% of participants receiving onabotulinumtoxin-A had a decrease of 50% or more of
headache free days compared to placebo. Also, the mean change from baseline in the frequency
of headaches per 30-day period was -6.1 for the onabotulinumtoxin-A group vs -3.1 for placebo
group (p=.013).6 NNT was calculated and are shown in table 2.
Table 2-Calculations for Mathew et al.
Group

ARR

NNT

Non-responder

0.11

9

Responder

0.28

4

The second study, conducted by Diener et al., was the second part of the PREENPT 2
trial that compared onabotulinumtoxin-A versus placebo to measure frequency of headaches in
adults over a 24-week period.7 Patients who qualified for the study were randomized in a 1:1
double-blind fashion to experimental group using onabotulinumtoxin- or placebo. 7 Throughout
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the entire double-blind phase, the participants, investigators, and experimenters were all masked
to the treatment-group.
Injections were administered at 31 fixed-sites intramuscularly. 7 The primary efficacy
endpoint of this study was mean change from baseline in frequency of headache days for the 28day period. A headache day was defined as a calendar day (24 hours) with four or more hours
consisting of a headache. Throughout the study, patient’s headaches were recorded using an
interactive voice response system and telephone diaries.
In the end of the 24 week period study, results proved that Onabotulinumtoxin-A was
significantly superior compared to placebo in reducing frequency of headaches compared to
baseline (-9.0 in Onabotulinumtoxin-A versus -6.7 in placebo group, p < 0.001). 7 Results showed
a 95% CI (-3.35, -1.31) which means that the researchers were 95% confident that the mean of
headache-free days for patients in the intervention group was between the values of -3.35 and 1.31.7
Vikelis et al. was an observational cohort study that used onabotulinumtoxin-A versus
patients baseline to measure the efficacy of onabotulinumtoxin-A decreasing frequency of
headaches.8 Headaches were recorded using diaries at each scheduled visit. For safety control,
patients were encouraged to report any side effects of the treatment either spontaneously or in
non-direct questioning. Patients who could not tolerate the treatment withdrew from the program.
Overall the intervention was considered generally safe and side effects were non-severe. 8
Of the 81 patients who did complete the study, results showed a significant decrease in
mean days out of the month between months 0-3 (21.3 +/- 5.4 versus 7.7 +/- 4.8; p-value
<0.001).8 This means that participants experienced on average only 7.7 days of headaches
compared to their baseline which was about 21.3 days, on a 30-day period.
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Discussion
All three studies conducted by Diener et al., Vikelis et al., and Mathew et al. showed
onabotulinumtoxin-A was able to decrease the frequency of headaches in adults with chronic
migraines.7,8 A decrease of 50% or more was observed in Mathew et. al study, while the other
two studies were able to show decrease of headache free days with p-values and CI.
Between all three studies, there is some variation in the amount of onabotulinumtoxin-A
used as intervention. Therefore, we can only use a range of onabotulinumtoxin-A to say what
amount is needed to reduce frequency of headache days. There was also difference in location of
where the onabotulinumtoxin-A was injected between the three studies. Two of the studies
injected in a total of 7 intramuscular sites, while the third study did not list their injection sites.
Also, two of the studies used a follow-the-pain strategy, while the third did not. This means,
additional dosing was allowed per protocol depending on the patient’s predominant pain and
severity of migraine.7 All three studies used different times periods for the duration of their
treatment. Time periods ranged from 12 weeks to 36 weeks. 6,7,8 The study conducted by Diener
et. al. also took into consideration other treatment options being used throughout the study, like
acute pain medication, while the others did not.
One limitation to this research, was the types of studies selected for my paper. The
observational cohort study provided limited data and statistical analysis. NNT could not be
calculated for this study since there was no control group. 8 RCTs are the gold standard for
clinical research and have a high impact on clinical guidelines. This is because RCTs have both
experimental and control groups that are randomized which reduces selection bias. Another
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limitation of the observational cohort was the high percent of early drop-outs before the end of
the study.8

Conclusion
All three studies showed that onabotulinumtoxin-A is able to decrease frequency of
headaches in adults with chronic migraines. Both of the RCTs provided significant data which
supported the use of onabotulinumtoxin-A for chronic migraines. The observation cohort was
able to prove efficacy by comparing end results to patient’s baseline. However, there is some
discrepancy between the studies as far as time periods, injection site, and amount of treatment
used.
Further research needs to be conducted to answer the clinical question “Does
onabotulinumtoxin-A decrease the frequency of headaches in adults with chronic migraines?”.
This selective EBM paper focused specifically on the frequency of migraines affected by the
onabotulinumtoxin-A treatment. The severity of migraines is another factor that needs to be
considered from the use of onabotulinumtoxin-A for migraines. Only two of the three articles
focused on severity of participant’s migraines. One study also looked at other acute pain
medications during the duration of the treatment. This gave researchers the ability to compare
onabotulinumtoxin-A to other migraine treatment options. Future research should focus on these
components, as well as longer time periods of treatment, consistency in amount used, and
specific injection sites to measure the effects of onabotulinumtoxin-A for chronic migraines.
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